14 Rallying Biotech Stocks Being Snapped Up By Insiders

Want to know the inside scoop? One of the best sources for what company insiders actually think about their companies is trends in insider buying.

Company insiders, such as members of the board and upper management, report when they personally buy shares in their company. This is seen by analysts as a very positive sign because who knows their companies better than they do?

To illustrate this idea, we ran a screen on the biotech industry for stocks currently rallying above their 20-day, 50-day, and 200-day moving averages. We then screened for those with the most significant net insider buying over the last six months, indicating these insiders are bullish on their companies.

‪Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬

‪

Your browser does not support iframes.

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these insiders are calling it right? Use this list as a starting point for your own analysis.

List sorted alphabetically.

1. Array BioPharma, Inc. (NASDAQ:ARRY): Focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. The stock is currently trading 25.36% above its 20-day moving average, 27.81% above its 50-day MA, and 21.14% above its 200-day MA. Over the last six months, insiders were net buyers of 170,695 shares, which represents about 0.42% of the company's 40.94M share float.

2. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. The stock is currently trading 24.72% above its 20-day moving average, 30.38% above its 50-day MA, and 13.94% above its 200-day MA. Over the last six months, insiders were net buyers of 15,458 shares, which represents about 0.04% of the company's 36.59M share float.

3. China Biologic Products, Inc. (NASDAQ:CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. The stock is currently trading 0.80% above its 20-day moving average, 1.76% above its 50-day MA, and 1.03% above its 200-day MA. Over the last six months, insiders were net buyers of 795,860 shares, which represents about 11.93% of the company's 6.67M share float.

4. Dyax Corp. (NASDAQ:DYAX): Engages in the discovery, development, and commercialization of novel biotherapeutics for unmet medical needs in the United States. The stock is currently trading 8.77% above its 20-day moving average, 15.72% above its 50-day MA, and 0.03% above its 200-day MA. Over the last six months, insiders were net buyers of 83,350 shares, which represents about 0.09% of the company's 89.50M share float.

5. Amicus Therapeutics, Inc. (NASDAQ:FOLD): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. The stock is currently trading 29.46% above its 20-day moving average, 72.08% above its 50-day MA, and 33.58% above its 200-day MA. Over the last six months, insiders were net buyers of 10,000 shares, which represents about 0.09% of the company's 11.39M share float.

6. GTX Inc. (NASDAQ:GTXI): Engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. The stock is currently trading 53.72% above its 20-day moving average, 85.35% above its 50-day MA, and 50.16% above its 200-day MA. Over the last six months, insiders were net buyers of 30,000 shares, which represents about 0.14% of the company's 21.03M share float.

7. Halozyme Therapeutics, Inc. (NASDAQ:HALO): Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The stock is currently trading 10.54% above its 20-day moving average, 16.89% above its 50-day MA, and 49.15% above its 200-day MA. Over the last six months, insiders were net buyers of 1,934,950 shares, which represents about 2.98% of the company's 64.95M share float.

8. Incyte Corporation (NASDAQ:INCY): Focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. The stock is currently trading 5.15% above its 20-day moving average, 19.12% above its 50-day MA, and 10.60% above its 200-day MA. Over the last six months, insiders were net buyers of 4,476,050 shares, which represents about 3.59% of the company's 124.66M share float.

9. Neurocrine Biosciences Inc. (NASDAQ:NBIX): Engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The stock is currently trading 12.27% above its 20-day moving average, 22.84% above its 50-day MA, and 33.59% above its 200-day MA. Over the last six months, insiders were net buyers of 103,400 shares, which represents about 0.21% of the company's 49.57M share float.

10. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI): Engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The stock is currently trading 9.71% above its 20-day moving average, 18.52% above its 50-day MA, and 7.81% above its 200-day MA. Over the last six months, insiders were net buyers of 3,000 shares, which represents about 0.04% of the company's 7.09M share float.

11. Repligen Corporation (NASDAQ:RGEN): Engages in the development and commercialization of therapies that deliver value to patients and clinicians in neurology, gastroenterology, and orphan diseases. The stock is currently trading 11.37% above its 20-day moving average, 17.26% above its 50-day MA, and 15.78% above its 200-day MA. Over the last six months, insiders were net buyers of 31,000 shares, which represents about 0.12% of the company's 26.64M share float.

12. Seattle Genetics Inc. (NASDAQ:SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. The stock is currently trading 6.38% above its 20-day moving average, 11.84% above its 50-day MA, and 5.93% above its 200-day MA. Over the last six months, insiders were net buyers of 1,147,052 shares, which represents about 1.01% of the company's 113.40M share float.

13. ViroPharma Inc. (VPHM): Engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. The stock is currently trading 3.83% above its 20-day moving average, 13.32% above its 50-day MA, and 44.66% above its 200-day MA. Over the last six months, insiders were net buyers of 2,020,227 shares, which represents about 3.09% of the company's 65.45M share float.

14. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. The stock is currently trading 12.75% above its 20-day moving average, 18.00% above its 50-day MA, and 4.40% above its 200-day MA. Over the last six months, insiders were net buyers of 1,351,460 shares, which represents about 2.45% of the company's 55.23M share float.

*Insider data sourced from Yahoo Finance, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

We only use your contact details to reply to your request for more information.We do not sell the personal contact data you submit to anyone else.

Thank you for your interest in Seeking Alpha PROWe look forward to contacting you shortly for a conversation.

Thank you for your interest in Seeking Alpha PRO

Our PRO subscription service was created for fund managers, and the cost of the product is
prohibitive for most individual investors.
If you are an investment professional with over $1M AUM and received this message
in error, click here and you will be contacted shortly.

Thank you for your interest in Seeking Alpha PROWe look forward to contacting you when we have an individual investor product ready!